The transfer of pravastatin in the dually perfused human placenta

J. Zarek, M. K. DeGorter, A. Lubetsky, R. B. Kim, C. A. Laskin, H. Berger, G. Koren

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

HMG-CoA reductase inhibitors (statins) are contraindicated during pregnancy. However, it has been suggested that the hydrophilic property of pravastatin prevents its placental transfer to the fetus, explaining neutral effects observed in controlled studies. Using the ex-vivo placental perfusion model, placental transfer of pravastatin (50 ng/ml) was determined. The mean maximum fetal concentration was 4.4 ng/ml. The transfer of pravastatin's across the placenta appears to be limited and slow. Combined with its rapid elimination half-life of 2 h and 50% protein binding, the transfer of pravastatin from maternal to fetal compartments is substantially more limited than observed in the perfusion experiments.

Original languageEnglish
Pages (from-to)719-721
Number of pages3
JournalPlacenta
Volume34
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Keywords

  • Cholesterol
  • Placental perfusion
  • Pravastatin
  • Pregnancy
  • Teratogenic

Fingerprint

Dive into the research topics of 'The transfer of pravastatin in the dually perfused human placenta'. Together they form a unique fingerprint.

Cite this